Sartorius: Upstream Bioprocessing Market Dominance
Former Senior Product Management Director at Sartorius Stedim Biotech
inpractise.com/articles/sartorius-dominating-upstream-bioprocessing-through-integrated-automation
Sartorius: Upstream Bioprocessing Market Dominance(August 18, 2025)
Former Senior Product Management Director at Sartorius Stedim Biotech
Interview Transcript
This is a snippet of the transcript.Contact Salesto get full access.
Amazing. A good way to start this conversation would be to understand how the competitive landscape for Sartorius is evolving. Is it evolving favorably or unfavorably? There are several ways to approach this, but perhaps you could share your perspective on how the competitive landscape is changing for Sartorius over the next five to 10 years.
We created a new automation system that is plug-and-play, enabling system integration with a bio-brain. You can plug in the ATF system to your SDR and suddenly have a concentrated fed-batch or run a perfusion process. This innovation changed the industry because competitors like Thermo Fisher only had commercial bioreactors. Sartorius changed the game by focusing on faster product development and more efficient process transfers. This led to a different discussion about adapting to life cycle needs when more product is required. Sartorius is now the unbeaten leader in upstream processes, which is crucial as upstream is the start of the process.
This is a snippet of the transcript.Contact Salesto get full access.
Related Content
Sartorius: Upstream Bioprocessing & Chinese Competition
Former Senior Product Management Director at Sartorius Stedim Biotech
Danaher & the Bioprocessing FDA Approval Process
Former Head of Sales, GE Life Sciences
Danaher Cytiva: History, Moat, and Bundling Pall Filters
Danaher, Sartorius, & an Overview of The Bioprocessing Environment
Former VP of Sales at Pall Corp
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.